ABSTRACT
COVID-19, a pandemic caused by severe acute respiratory syndrome (SARS) corona virus-2 has been a worldwide challenge for the entire mankind. However, a safe and efficacious vaccine would be clinically valuable to reduce the risks of COVID-19. In this study, we aimed to assess the seroprevalence of the Neutralizing IgG Antibodies six months after completion of both the doses of Covishield Vaccination (ChAdox1 nCoV-19) and compare it with the IgG titres one month after the first dose and one month after the second dose of the vaccine respectively. The efficacy, safety and comorbidities related to the vaccine were also assessed at different time intervals. The levels of IgG antibodies were estimated in 72 subjects from the Teerthanker Mahaveer Medical College & Research Centre (who turned up after six months of the complete regimen of Covishield Vaccination) using the Enzyme-Linked Immunosorbent Assay (ELISA) Technique. A highly significant increase (p= 0.00) in the neutralizing Antibodies titre was seen in fully vaccinated individuals post six months when compared to the titres of post one month of 1st & 2nddoses. It can therefore be concluded that (ChAdox1 nCoV-19) Covishield Vaccination if administered in full regimen has both acceptable efficacies as well as safety profile. Hence, a complete vaccine regimen may prove as an effective strategy against COVID-19 and consequent minimization of long-term morbid effects. © 2022 International Journal of Health Sciences.